Advertisement

Usefulness of Cardiac Biomarker Score for Risk Stratification in Stable Patients Undergoing Elective Cardiac Evaluation Across Glycemic Status

Published:December 07, 2012DOI:https://doi.org/10.1016/j.amjcard.2012.10.027
      Several clinically available cardiac biomarkers have established their prognostic value in patients with acute coronary syndromes. However, their relative prognostic significance in stable subjects has not been prospectively validated, either individually or in combination. The aim of this study was to evaluate the extent to which B-type natriuretic peptide, myeloperoxidase, and high-sensitivity C-reactive protein alone or together could be prognostic biomarkers in 3,635 consecutive stable patients without acute coronary syndrome who underwent elective diagnostic coronary angiography. After adjusting for traditional risk factors and renal function, each of the markers monitored was a significant predictor of incident major adverse cardiovascular events (death, nonfatal myocardial infarction, and stroke) over 3 years. A cardiac biomarker score based on the sum total of “positive” biomarkers provided independent prediction of future risk for incident major adverse cardiovascular events at 3 years (hazard ratio [HR] 7.61, 95% confidence interval [CI] 4.98 to 11.65, p <0.001), even after adjusted for traditional risk factors (HR 6.11, 95% CI 3.98 to 9.38, p <0.001). A positive cardiac biomarker score remained a strong and independent predictor of 3-year risk for major adverse cardiovascular events among those with normal glycemic control (HR 4.24, 95% CI 1.96 to 9.18, p <0.001), those with prediabetes (HR 7.62, 95% CI 3.87 to 15.01, p <0.001), and those with diabetes (HR 5.61, 95% CI 2.55 to 12.33, p <0.001), as well as within subjects without significant angiographic evidence of coronary artery disease (HR 10.82, 95% CI 3.82 to 30.6, p <0.001). In conclusion, an integrated assessment of cardiac biomarkers may provide independent prognostic value for long-term adverse clinical events in stable cardiac patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sabatine M.S.
        • Morrow D.A.
        • de Lemos J.A.
        • Gibson C.M.
        • Murphy S.A.
        • Rifai N.
        • McCabe C.
        • Antman E.M.
        • Cannon C.P.
        • Braunwald E.
        Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.
        Circulation. 2002; 105: 1760-1763
        • de Lemos J.A.
        • Morrow D.A.
        • Bentley J.H.
        • Omland T.
        • Sabatine M.S.
        • McCabe C.H.
        • Hall C.
        • Cannon C.P.
        • Braunwald E.
        The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
        N Engl J Med. 2001; 345: 1014-1021
        • Brennan M.L.
        • Penn M.S.
        • Van Lente F.
        • Nambi V.
        • Shishehbor M.H.
        • Aviles R.J.
        • Goormastic M.
        • Pepoy M.L.
        • McErlean E.S.
        • Topol E.J.
        • Nissen S.E.
        • Hazen S.L.
        Prognostic value of myeloperoxidase in patients with chest pain.
        N Engl J Med. 2003; 349: 1595-1604
        • Ridker P.M.
        • Hennekens C.H.
        • Buring J.E.
        • Rifai N.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        N Engl J Med. 2000; 342: 836-843
        • Morrow D.A.
        • Braunwald E.
        Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
        Circulation. 2003; 108: 250-252
      1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
      2. Standards of medical care in diabetes—2012.
        Diabetes Care. 2012; 35: S11-S63
        • Tang W.H.
        • Wu Y.
        • Nicholls S.J.
        • Hazen S.L.
        Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease.
        Clin Chem. 2011; 57: 33-39
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr., A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Ridker P.M.
        • Rifai N.
        • Clearfield M.
        • Downs J.R.
        • Weis S.E.
        • Miles J.S.
        • Gotto Jr., A.M.
        Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
        N Engl J Med. 2001; 344: 1959-1965
        • Ridker P.M.
        • Rifai N.
        • Rose L.
        • Buring J.E.
        • Cook N.R.
        Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
        N Engl J Med. 2002; 347: 1557-1565
        • Tang W.H.
        • Shrestha K.
        • Van Lente F.
        • Troughton R.W.
        • Martin M.G.
        • Borowski A.G.
        • Jasper S.
        • Klein A.L.
        Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure.
        Am J Cardiol. 2008; 101: 370-373
        • Anand S.S.
        • Yusuf S.
        C-reactive protein is a bystander of cardiovascular disease.
        Eur Heart J. 2010; 31: 2092-2096
        • Elliott P.
        • Chambers J.C.
        • Zhang W.
        • Clarke R.
        • Hopewell J.C.
        • Peden J.F.
        • Erdmann J.
        • Braund P.
        • Engert J.C.
        • Bennett D.
        • Coin L.
        • Ashby D.
        • Tzoulaki I.
        • Brown I.J.
        • Mt-Isa S.
        • McCarthy M.I.
        • Peltonen L.
        • Freimer N.B.
        • Farrall M.
        • Ruokonen A.
        • Hamsten A.
        • Lim N.
        • Froguel P.
        • Waterworth D.M.
        • Vollenweider P.
        • Waeber G.
        • Jarvelin M.R.
        • Mooser V.
        • Scott J.
        • Hall A.S.
        • Schunkert H.
        • Anand S.S.
        • Collins R.
        • Samani N.J.
        • Watkins H.
        • Kooner J.S.
        Genetic loci associated with C-reactive protein levels and risk of coronary heart disease.
        JAMA. 2009; 302: 37-48
        • Hazen S.L.
        • Zhang R.
        • Shen Z.
        • Wu W.
        • Podrez E.A.
        • MacPherson J.C.
        • Schmitt D.
        • Mitra S.N.
        • Mukhopadhyay C.
        • Chen Y.
        • Cohen P.A.
        • Hoff H.F.
        • Abu-Soud H.M.
        Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo.
        Circ Res. 1999; 85: 950-958
        • Schmitt D.
        • Shen Z.
        • Zhang R.
        • Colles S.M.
        • Wu W.
        • Salomon R.G.
        • Chen Y.
        • Chisolm G.M.
        • Hazen S.L.
        Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum.
        Biochemistry. 1999; 38: 16904-16915
        • Vita J.A.
        • Brennan M.L.
        • Gokce N.
        • Mann S.A.
        • Goormastic M.
        • Shishehbor M.H.
        • Penn M.S.
        • Keaney Jr., J.F.
        • Hazen S.L.
        Serum myeloperoxidase levels independently predict endothelial dysfunction in humans.
        Circulation. 2004; 110: 1134-1139
        • Nicholls S.J.
        • Hazen S.L.
        Myeloperoxidase and cardiovascular disease.
        Arterioscler Thromb Vasc Biol. 2005; 25: 1102-1111
        • Nicholls S.J.
        • Hazen S.L.
        Myeloperoxidase, modified lipoproteins, and atherogenesis.
        J Lipid Res. 2009; 50: S346-S351
        • Tang W.H.
        • Shrestha K.
        • Troughton R.W.
        • Borowski A.G.
        • Klein A.L.
        Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure.
        Congest Heart Fail. 2011; 17: 105-109
        • Nicholls S.J.
        • Tang W.H.
        • Brennan D.
        • Brennan M.L.
        • Mann S.
        • Nissen S.E.
        • Hazen S.L.
        Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain.
        Clin Chem. 2011; 57: 1762-1770
        • Reichlin T.
        • Socrates T.
        • Egli P.
        • Potocki M.
        • Breidthardt T.
        • Arenja N.
        • Meissner J.
        • Noveanu M.
        • Reiter M.
        • Twerenbold R.
        • Schaub N.
        • Buser A.
        • Mueller C.
        Use of myeloperoxidase for risk stratification in acute heart failure.
        Clin Chem. 2010; 56: 944-951
        • Naruko T.
        • Furukawa A.
        • Yunoki K.
        • Komatsu R.
        • Nakagawa M.
        • Matsumura Y.
        • Shirai N.
        • Sugioka K.
        • Takagi M.
        • Hozumi T.
        • Itoh A.
        • Haze K.
        • Yoshiyama M.
        • Becker A.E.
        • Ueda M.
        Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina.
        Heart. 2010; 96: 1716-1722
        • Tang W.H.
        B-type natriuretic peptide: a critical review.
        Congest Heart Fail. 2007; 13: 48-52
        • Fonarow G.C.
        • Peacock W.F.
        • Phillips C.O.
        • Givertz M.M.
        • Lopatin M.
        • ADHERE Scientific Advisory Committee and Investigators
        Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.
        J Am Coll Cardiol. 2007; 49: 1943-1950
        • Tabak A.G.
        • Herder C.
        • Rathmann W.
        • Brunner E.J.
        • Kivimaki M.
        Prediabetes: a high-risk state for diabetes development.
        Lancet. 2012; 379: 2279-2290